JAMA Oncology : Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib
- Author
- American Medical Association, 2017
- Published
- Thu 21 Nov 2024
- Episode Link
- https://edhub.ama-assn.org/jn-learning/audio-player/10.1001/jamaoncol.2024.5617
Interview with Hagop Kantarjian, MD, author of Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial. Hosted by Vivek Subbiah, MD.
Related Content:
